Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: Evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine

Drug Metabolism Reviews

Volumn 31, Issue 2, 1999, Pages 545-560

  Schmider, Jürgen ^a,b   Von Moltke, Lisa L ^a   Shader, Richard I ^a   Harmatz, Jerold S ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Amitriptyline; Fluoxetine; In vitro in vivo scaling; Pharmacokinetic interaction; Prediction

Indexed keywords

AMITRIPTYLINE; CYTOCHROME P450; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; DICLOFENAC 4' HYDROXYLASE; FLUOXETINE; NORFLUOXETINE; PHENACETIN O DEETHYLASE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG LIVER LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUOXETINE; HUMANS; MODELS, BIOLOGICAL;

EID: 0032925505     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101935     Document Type: Conference Paper

References (48)

1. G. R. Wilkinson, Clearance approaches in pharmacology, Pharmacol. Rev., 39, 1-47 (1987).
2. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, and R. I. Shader, Metabolism of amitriptyline by human liver microsomes; identification of cytochrome P450 enzymes involved, Pharmacopsychiatry, 30, 219 (1997).
3. T. Andersson, J. O. Miners, M. E. Veronese, and D. J. Birkett, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms, Br. J. Clin. Pharmacol., 38, 131-137 (1994).
4. J. Schmider, D. J. Greenblatt, L. L. von Moltke, and R. I. Shader, Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions; implications for diazepam disposition in humans, J. Clin. Psychopharmacol, 16, 267-272 (1996).
5. L. L. von Moltke, D. J. Greenblatt, J. S. Harmatz, S. X. Duan, L. M. Harrel, M. M. Cotreau-Bibbo, G. A. Pritchard, C. E. Wright, and R. I. Shader, Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole, J. Pharmacol. Exp. Ther., 276, 370-379 (1996).
6. L. L. von Moltke, D. J. Greenblatt, M. M. Cotreau-Bibbo, J. S. Harmatz, and R. I. Shader, Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine, Br. J. Clin. Pharmacol., 38, 23-31 (1994).
7. J. Schmider, D. J. Greenblatt, J. S. Harmatz, and R. I. Shader, Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation, Br. J. Clin. Pharmacol, 41, 593-604 (1996).
8. L. L. von Moltke, D. J. Greenblatt, J. Schmider, J. S. Harmatz, and R. I. Shader, Metabolism of drugs by cytochrome P450 3A isoforms, Clin. Pharmacokinet, 29 (Suppl. 1), 33-43 (1995).
9. J. Schmider, D. J. Greenblatt, S. M. Fogelman, L. L. von Moltke, and R. I. Shader, Metabolism of dextromethorphan in vitro: Involvement of cytochromes P450 2D6, 3A3/4, with a possible role of 2E1, Biopharm. Drug. Dispos., 18, 227-240 (1997).
10. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, and R. I Shader, Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O-and N-demethylation, Br. J. Clin. Pharmacol, 41, 339-343 (1996).
11. J. Schmider, D. J. Greenblatt, L. L. von Moltke, D. Karsov, and R. I. Shader, Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin 4-hydroxylation, Br. J. Clin. Pharmacol, 44, 495-498 (1997).
12. J. Schmider, D. J. Greenblatt, L. L. von Moltke, D. Karsov, R. Vena, H. L. Friedman, and R. I. Shader, Biotransformation of mestranol to ethinyl-estradiol in vitro: the role of cytochrome P450 2C9 and metabolic inhibitors, J. Clin. Pharmacol, 37, 193-200 (1997).
13. J. Schmider, J. D. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. X. Duan, D. Karsov, and R. I. Shader, Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies, Pharmacology, 52, 125-134 (1996).
14. L. L. von Moltke, D. J. Greenblatt, S. X. Duan, J. Schmider, L. Kudchadker, S. M. Fogelman, J. S. Harmatz, and R. I. Shader, Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine, Psychopharmacology, 128, 398-407 (1996).
15. L. L. von Moltke, D. J. Greenblatt, S. X. Duan, J. Schmider, C. E. Wright, J. S. Harmatz, and R. I. Shader, Human cytochromes mediating N-demethylation of fluoxetine in vitro, Psychopharmacology, 132, 402-407 (1997).
16. L. L. von Moltke, D. J. Greenblatt, J. Schmider, S. X. Duan, C. E. Wright, J. S. Harmatz, and R. I. Shader, Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents, J. Clin. Pharmacol., 36, 783-791 (1996).
17. D. N. Bailey and R. F. Shaw, Interpretation of blood and tissue concentrations in fatal self-ingested overdose involving amitriptyline: An update (1978-1979), J. Anal. Toxicol., 4, 232-236 (1980).
18. A. D. Fraser, A. F. Isner, and R. A. Perry, Distribution of trimipramine and its major metabolites in a fatal overdose case, J. Anal. Toxicol., 11, 168-170 (1987).
19. B. Levine, A. J. Jenkins, and J. E. Smialek, Distribution of sertraline in postmortem cases, J. Anal. Toxicol., 18, 272-274 (1994).
20. R. J. Wong, The determination of the triazolobenzodiazepine triazolam in post mortem samples, J. Anal. Toxicol., 8, 10-13 (1984).
21. H. Kurz and B. Fichtl, Binding of drugs to tissues, Drug Metab. Rev., 14, 467-510 (1983).
22. G. M. Pacifici and A. Viani, Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences, Clin. Pharmacokinet., 23, 449-468 (1992).
23. G. Schuhmann, B. Fichtl, and H. Kurz, Prediction of drug distribution in vivo on the basis of in vitro binding data, Biopharm. Drug Dispos., 8, 73-86 (1987).
24. C. H. Chou, A. M. Evans, G. Fornasini, and M. Rowland, Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver, Drug Metab. Dispos., 21, 933-938 (1993).
25. Y. Igari, Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano. Tissue distribution of 14C-diazepam and its metabolites in rats, Drug Metab. Dispos., 10, 676-679 (1982).
26. J. M. Scavone, H. Friedman, D. J. Greenblatt, and R. I. Shader, Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats, Arzn. Forsch., 37, 2-6 (1996).
27. D. J. Greenblatt, L. L. von Moltke, J. Schmider, J. S. Harmatz, and R. I. Shader, Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies, J. Clin. Pharmacol., 36, 792-798 (1996).
28. R. S. Obach, Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol, Drug Metab. Dispos., 25, 1359-1369 (1997).
29. N. Müller, J. Brockmöller, and I. Roots, Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele - a slowly reversible interaction with fluoxetine, Ther. Drug Monit., 13, 533-536 (1991).
30. S. Vandel, G. Bertschy, B. Bonin, S. Nezelof, T. H. Francois, B. Vandel, D. Sechter, and P. Bizouard, Tricyclic antidepressant plasma levels after fluoxetine addition, Neuropsychobiology, 25, 202-207 (1992).
31. D. E. Rollins, G. Alvan, L. Bertilsson, J. R. Gillette, B. Mellstrom, F. Sjoqvist, and L. Traskman, Interindividual differences in amitriptyline demethylation, Clin. Pharmacol. Ther., 28, 121-129 (1980).
32. P. Ghahramani, S. W. Ellis, M. S. Lennard, L. E. Ramsay, and G. T. Tucker, Cytochromes p450 mediating the N-demethylation of amitriptyline, Br. J. Clin. Pharmacol., 43, 137-144 (1997).
33. J. Schmider, D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, and R. I. Shader, N-demethylation of amitriptyline in vitro: Role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors, J. Pharmacol. Exp. Ther., 275, 592-597 (1995).
34. K. Venkatakrishnan, D. J. Greenblatt, L. L. von Moltke, J. Schmider, J. S. Harmatz, and R. I. Shader, Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP2C19 and 3A4, J. Clin. Pharmacol., 38, 112-121 (1998).
35. O. V. Olesen and K. Linnet, Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 isozymes, Pharmacology, 55, 235-243 (1997).
36. P. Baumann, M. Jonzier-Perey, L. Koeb, A. Kupfer, D. Tinguely, and J. Schopf, Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin, Int. Clin. Psychopharmacol., 1, 102-112 (1986).
37. U. Breyer-Pfaff, B. Pfandl, K. Nill, E. Nusser, C. Monney, M. Jonzier-Perey, D. Baettig, and P. Baumann, Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes, Clin. Pharmacol. Ther., 52, 350-358 (1992).
38. L. Lemberger, R. F. Bergstrom, R. L. Wolen, N. A. Farid, G. G. Enas, and G. R. Aronoff, Fluoxetine: Clinical pharmacology and physiologic disposition, J. Clin. Psychiatry, 46(3 Pt. 2), 14-19 (1985).
39. J. van Harten, Clinical pharmacokinetics of selective serotonin reuptake inhibitors, Clin. Pharmacokinet, 24, 203-220 (1993).
40. H. K. Crewe, M. S. Lennard, G. T. Tucker, F. R. Woods, and R. E. Haddock, The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes, Br. J. Clin. Pharmacol., 34, 262-265 (1992).
41. S. V. Otton, D. Wu, R. T. Joffe, S. W. Cheung, and E. M. Sellers, Inhibition by fluoxetine of cytochrome P450 2D6 activity, Clin. Pharmacol. Ther., 53, 401-409 (1993).
42. S. H. Preskorn, J. Alderman, M. Chung, W. Harrison, M. Messig, and S. Harris, Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine, J. Clin. Psychopharmacol., 14, 90-98 (1994).
43. C. E. Wright, T. A. Lasher-Sisson, R. C. Steenwyk, and C. N. Swanson, A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine, Pharmacotherapy, 12, 103-106 (1992).
44. L. L. von Moltke, D. J. Greenblatt, M. M. Cotreau-Bibbo, S. X. Duan, J. S. Harmatz, and R. I. Shader, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo, J. Pharmacol. Exp. Ther., 268, 1278-1283 (1994).
45. A. El-Yazigi, K. Chaleby, A. Gad, and D. A. Raines, Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone, J. Clin. Pharmacol., 35, 17-21 (1995).
46. L. L. von Moltke, D. J. Greenblatt, S. X. Duan, J. S. Harmatz, and R. I. Schader, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction, J. Clin. Pharmacol., 34, 1222-1227 (1994).
47. L. L. von Moltke, D. J. Greenblatt, S. X. Duan, J. S. Harmatz, C. E. Wright, and R. I. Shader, Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to phamacokinetic interactions in vivo, J. Clin. Psychopharmacol., 36, 104-113 (1996).
48. L. L. von Moltke, D. J. Greenblatt, J. Schmider, C. E. Wright, J. S. Harmatz, and R. I. Shader, In vitro approaches to predicting drug interactions in vivo, Biochem. Pharmacol., 55, 113-122 (1997).